July 1, 2015
Find information regarding calculating the cost basis of Common Stock relating to the Baxalta spin-off from Baxter on July 1, 2015.
Why did Baxter spin off Baxalta?
Baxter International today spun off its Baxter BioScience global biopharmaceutical business into Baxalta, saying the new company will focus on developing new treatments for people with orphan diseases and underserved conditions.
When did Shire acquire Baxalta?
In January 2016, after six months of negotiations, the company agreed to be acquired by Shire for $32 billion. The deal was completed on 3 June 2016.
When did Baxter International go public?
Kolff’s research effort on the production of artificial kidneys. In 1956, Baxter introduced the first commercially-built kidney dialysis system, representing the company’s first move into a field in which it would become known as an innovator. Baxter shares began trading on the New York Stock Exchange in 1961.
How much did Takeda pay for Shire?
This was linked to Takeda increasing its offer for the entire issued and to be issued ordinary capital of Shire; the highest offer made saw Shire’s shareholders receiving $30.33 in cash for each Shire share, or 0.839 new Takeda shares.
Is Baxter part of Takeda?
Baxter International of the US and Japan’s largest drugmaker Takeda Pharmaceutical Company have signed a development, license and technology transfer agreement, which gives Takeda an exclusive licence to Baxter’s Vero cell culture-based influenza vaccines for the Japanese market.
Does Shire still exist?
Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions….Shire (pharmaceutical company)
| Type | Subsidiary |
|---|---|
| Founded | 1986 |
| Defunct | 2019 |
| Fate | Acquired by Takeda |
| Headquarters | Massachusetts, United States |
What drugs does shire make?
Shire, located in Wayne, Pennsylvania, manufactures and sells pharmaceuticals, including Adderall XR, Vyvanse and Daytrana, which are approved for the treatment of attention deficit hyperactivity disorder (ADHD), and Pentasa and Lialda, which are approved for the treatment of mild to moderate active ulcerative colitis.
Who is the CEO of Baxter?
José E. Almeida (Jan 1, 2016–)
Baxter International/CEO
When did Baxter spin off Baxalta into bxlt?
On 1 July 2015, Baxter ( BAX) spun-off Baxalta ( BXLT) and distributed shares of BXLT to holders of BAX shares. Shareholders of BAX on record as of the close of business on 17 June 2015 received one share of BXLT for every share of BAX held. I bought 37 shares of BAX in December 2013 at a price of $67.71 per share.
Is the Baxter spin-off a tax free distribution?
The spin-off has been structured as a tax-free distribution for U.S. federal income tax purposes. Details of the spin-off are available on Baxter’s website and includes information on cost-basis treatment for BAX shares.
How many shares of BAX are in divgro?
Shareholders of BAX on record as of the close of business on 17 June 2015 received one share of BXLT for every share of BAX held. I bought 37 shares of BAX in December 2013 at a price of $67.71 per share. Consequently, I received 37 shares of BXLT as a result of the spin-off. With this addition, DivGro now contains 47 shares.
What was the closing price of Bax in 2015?
To determine the fair market value of BAX and BXLT shares, use the closing price on 1 July 2015 for BAX ($38.86 per share) and BXLT ($31.50 per share).
